These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 36332445)
1. Vaccination as a therapeutic strategy for Nasopharyngeal carcinoma. Huang J; Harris E; Lorch J Oral Oncol; 2022 Dec; 135():106083. PubMed ID: 36332445 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic approaches in nasopharyngeal carcinoma. Chow JC; Ngan RK; Cheung KM; Cho WC Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154 [No Abstract] [Full Text] [Related]
3. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma. Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X Front Immunol; 2022; 13():1079515. PubMed ID: 36713430 [TBL] [Abstract][Full Text] [Related]
4. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit. Nickles E; Dharmadhikari B; Yating L; Walsh RJ; Koh LP; Poon M; Tan LK; Wang LZ; Ang Y; Asokumaran Y; Chong WQ; Huang Y; Loh KS; Tay J; Soo R; Koh M; Ho LP; Chan M; Niam M; Soh M; Luah YH; Lim CM; Kaliaperumal N; Au VB; Talib NBSN; Sng R; Connolly JE; Goh BC; Schwarz H Cancer Immunol Immunother; 2022 Jun; 71(6):1531-1543. PubMed ID: 34661709 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma. Hong M; Tang K; Qian J; Deng H; Zeng M; Zheng S; Ding K; Du Y; Sun R Crit Rev Oncog; 2018; 23(3-4):219-234. PubMed ID: 30311576 [TBL] [Abstract][Full Text] [Related]
6. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657 [TBL] [Abstract][Full Text] [Related]
7. Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading? Juarez-Vignon Whaley JJ; Afkhami M; Onyshchenko M; Massarelli E; Sampath S; Amini A; Bell D; Villaflor VM Curr Treat Options Oncol; 2023 Sep; 24(9):1138-1166. PubMed ID: 37318724 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic vaccination strategies to treat nasopharyngeal carcinoma. Taylor GS; Steven NM Chin Clin Oncol; 2016 Apr; 5(2):23. PubMed ID: 27121883 [TBL] [Abstract][Full Text] [Related]
10. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy. Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320 [TBL] [Abstract][Full Text] [Related]
11. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466 [TBL] [Abstract][Full Text] [Related]
12. Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer. Lee AZE; Tan LSY; Lim CM Oral Oncol; 2018 Sep; 84():61-70. PubMed ID: 30115477 [TBL] [Abstract][Full Text] [Related]
13. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma. Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review). Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358 [TBL] [Abstract][Full Text] [Related]
15. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma. Fung SY; Lam JW; Chan KC Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878 [TBL] [Abstract][Full Text] [Related]
16. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy. Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378 [TBL] [Abstract][Full Text] [Related]
17. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma. Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566 [TBL] [Abstract][Full Text] [Related]
18. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections. Ramayanti O; Verkuijlen SAWM; Novianti P; Scheepbouwer C; Misovic B; Koppers-Lalic D; van Weering J; Beckers L; Adham M; Martorelli D; Middeldorp JM; Pegtel DM Int J Cancer; 2019 May; 144(10):2555-2566. PubMed ID: 30411781 [TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review. Xue F; He X Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318 [TBL] [Abstract][Full Text] [Related]
20. Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein-Barr Virus Infection. Liu X; Deng Y; Huang Y; Ye J; Xie S; He Q; Chen Y; Lin Y; Liang R; Wei J; Li Y; Zhang J Curr Oncol; 2022 Aug; 29(9):6035-6052. PubMed ID: 36135044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]